Hopes weren’t very high ahead of the full readout from Novartis’s now-infamous Phase III Lp(a)HORIZON trial of pelacarsen, its lipoprotein(a)-reducing candidate that failed to meet the trial’s endpoint in September. Turns out they could be lower.
We dig into the data behind the endpoint miss and its read-through to other similar (in principle) drugs in development, as well as a status check on the next wave of NAS—excuse us, MASH—drugs.
Final Nail In The Coffin?
Pursuing Lp(a) lowering as a means of reducing cardiovascular outcomes seemed like a good idea. The lipid is, after all, a strong genetic risk factor for heart disease, and current drugs like statins do not lower it, instead focusing on low-density lipoprotein reductions.
That thesis had come into question following Novartis’s much-publicized Phase III failure, leading to a stock rout among other pharma stocks, especially those developing treatments that target Lp(a) lowering.
Now, researchers are leaving the door cracked just a tiny bit for other competitors, while the full readout closes the said door completely on any commercial potential of the drug.
The full Lp(a)HORIZON data, published in the New England Journal of Medicine alongside a Nov. 7 presentation at the American Heart Association Scientific Sessions in Chicago, confirmed the scale of the miss.
The secondary prevention trial enrolled 8,322 patients with established cardiovascular disease, randomized to a once-monthly 80mg injection of pelacarsen or placebo, on top of background lipid-lowering therapy including maximally tolerated statins and, in some cases, PCSK9 inhibitors.
Pelacarsen did what it was designed to do biologically.